EUVIMEDEUVIMED entdecken
Crossref

A triple crosslinked micelle-hydrogel lacrimal implant for localized and prolonged therapy of glaucoma

Jingyi Zhao, Jian Xiong, Yun Ning, Jiansong Zhao, Zhipeng Wang, Linhui Long, Haibing He, Jingxing Gou, Tian Yin, Xing Tang, Yu Zhang

European Journal of Pharmaceutics and Biopharmaceutics · 2023

DOI: 10.1016/j.ejpb.2023.02.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Jingyi Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China. Hauptthemen laut MEDLINE: Lacrimal Apparatus, Glaucoma, Prostaglandins F, Synthetic, Ocular Hypertension. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Shenyang Pharmaceutical University, Liaoning Province Doctoral Start-up Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glaucoma is a chronic disease that requires lifelong treatment, whereas, discomfort caused by frequent medication may affect the quality of life. Moreover, the therapeutic efficacy of traditional local administration was unsatisfactory due to the rapid ocular clearance mechanism and the ocular barrier. Herein, a triple crosslinked micelle-hydrogel lacrimal implant with low polymer content was fabricated for localized and prolonged therapy of glaucoma. Latanoprost and timolol were simultaneously entrapped in the PEG-PLA micelles with high encapsulation efficiency and further loaded into the triple crosslinked hydrogel, facilitating a double sustained release of drugs. Subsequently, the implant was constructed by a unique molecular orientation fixation technology, which enables the implant to be fixed in the lacrimal duct. The triple crosslinked micelle-hydrogel lacrimal implant manifested a distinguished physicochemical characterization to sustain the release of latanoprost and timolol. In vitro release experiment demonstrated the duration of two drugs was extended for up to 28 days. The in vivo test of elevated intraocular pressure (IOP) in a rabbit model revealed that the IOP-lowering effects were sustained longer than 28 days as expected. The relative pharmacological availability (PA) of lacrimal implants was 5.7 times greater than that of the eye drops. The results of the studies on ocular irritation and histological examination demonstrated the good safety of the lacrimal implant. In conclusion, the triple crosslinked micelle-hydrogel lacrimal implant could effectively lower the IOP with splendid compatibility, demonstrating the promising prospect in the long-term noninvasive treatment of glaucoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lacrimal ApparatusGlaucomaProstaglandins F, SyntheticOcular HypertensionAnimalsRabbitsMicellesTimololLatanoprostHydrogelsAntihypertensive AgentsQuality of LifeIntraocular PressureTreatment Outcome

Stichwörter der Autor:innen

GlaucomaHydrogelImplantLacrimalMicelleTriple crosslinked

Substanzen

MicellesTimololLatanoprostHydrogelsAntihypertensive AgentsProstaglandins F, Synthetic

Autor:innen und Institutionen

  • Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China.
  • School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China.
  • Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China. Electronic address: pharmzy@163.com.

Förderung

  • National Key Research and Development Program of China
  • Shenyang Pharmaceutical University
  • Liaoning Province Doctoral Start-up Foundation
  • Liaoning Provincial Department of Human Resources and Social Security
  • Shenyang Science and Technology Bureau
  • Ministry of Science and Technology of the People's Republic of China
  • Liaoning Revitalization Talents Program
  • Shenyang University

Zitieren

APA

Zhao, J., Xiong, J., Ning, Y., Zhao, J., Wang, Z., Long, L., He, H., Gou, J., Yin, T., Tang, X., & Zhang, Y. (2023). A triple crosslinked micelle-hydrogel lacrimal implant for localized and prolonged therapy of glaucoma. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.02.011

Vancouver

Zhao J, Xiong J, Ning Y, Zhao J, Wang Z, Long L, et al. A triple crosslinked micelle-hydrogel lacrimal implant for localized and prolonged therapy of glaucoma. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2023.02.011

BibTeX
@article{Zhao2023,
  author = {Zhao, Jingyi and Xiong, Jian and Ning, Yun and Zhao, Jiansong and Wang, Zhipeng and Long, Linhui and He, Haibing and Gou, Jingxing and Yin, Tian and Tang, Xing and Zhang, Yu},
  title = {A triple crosslinked micelle-hydrogel lacrimal implant for localized and prolonged therapy of glaucoma},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2023},
  doi = {10.1016/j.ejpb.2023.02.011}
}
Kostenlos starten →